keyword
MENU ▼
Read by QxMD icon Read
search

Parkinson drugs trials

keyword
https://www.readbyqxmd.com/read/29113464/a-new-treatment-strategy-for-parkinson-s-disease-through-the-gut-brain-axis-the-glucagon-like-peptide-1-receptor-pathway
#1
Dong Seok Kim, Ho-Il Choi, Yun Wang, Yu Luo, Barry J Hoffer, Nigel H Greig
Molecular communications in the gut-brain axis, between the central nervous system and the gastrointestinal tract, are critical for maintaining healthy brain function, particularly in aging. Epidemiological analyses indicate type 2 diabetes mellitus (T2DM) is a risk factor for neurodegenerative disorders including Alzheimer's disease (AD) and Parkinson's diseases (PD) for which aging shows a major correlative association. Common pathophysiological features exist between T2DM, AD, and PD, including oxidative stress, inflammation, insulin resistance, abnormal protein processing, and cognitive decline, and suggest that effective drugs for T2DM that positively impact the gut-brain axis could provide an effective treatment option for neurodegenerative diseases...
September 2017: Cell Transplantation
https://www.readbyqxmd.com/read/29111419/diagnosis-of-multiple-system-atrophy
#2
REVIEW
Jose-Alberto Palma, Lucy Norcliffe-Kaufmann, Horacio Kaufmann
Multiple system atrophy (MSA) may be difficult to distinguish clinically from other disorders, particularly in the early stages of the disease. An autonomic-only presentation can be indistinguishable from pure autonomic failure. Patients presenting with parkinsonism may be misdiagnosed as having Parkinson disease. Patients presenting with the cerebellar phenotype of MSA can mimic other adult-onset ataxias due to alcohol, chemotherapeutic agents, lead, lithium, and toluene, or vitamin E deficiency, as well as paraneoplastic, autoimmune, or genetic ataxias...
October 23, 2017: Autonomic Neuroscience: Basic & Clinical
https://www.readbyqxmd.com/read/29103053/domperidone-for-hypotension-in-parkinson-s-disease-a-systematic-review
#3
Stephen Bacchi, Ivana Chim, Philippe Kramer, Ronald B Postuma
BACKGROUND: Domperidone is a proposed treatment of orthostatic hypotension (OH) in Parkinson's disease (PD). However, domperidone use in PD is tempered by concerns regarding QT prolongation and ventricular tachyarrhythmia and sudden cardiac death (VT/SCD). OBJECTIVE: The aim is to identify peer-reviewed studies in which either (1) the effect of domperidone on blood pressure in patients with PD, or (2) the adverse effects associated with domperidone use in PD patients has been reported...
2017: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/29103048/treadmill-training-with-cues-and-feedback-improves-gait-in-people-with-more-advanced-parkinson-s-disease
#4
Valeria Studer, Roberto Maestri, Ilaria Clerici, Letizia Spina, Ilaria Zivi, Davide Ferrazzoli, Giuseppe Frazzitta
BACKGROUND: Gait disturbances in Parkinson's disease (PD) are highly disabling and poorly responsive to drugs, especially in advanced stages. While the efficacy of a treadmill training based on external feedback and cues (treadmill-plus) on gait disturbances in early PD stages is demonstrated, no definitive evidence exists about advanced stages. OBJECTIVE: We aimed to evaluate the feasibility and the effects of a treadmill-plus training on gait disturbances in advanced PD...
2017: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/29064136/pyridoxamine-a-novel-treatment-for-schizophrenia-with-enhanced-carbonyl-stress
#5
Masanari Itokawa, Mitsuhiro Miyashita, Makoto Arai, Takashi Dan, Katsuyoshi Takahashi, Taro Tokunaga, Kayo Ishimoto, Kazuya Toriumi, Tomoe Ichikawa, Yasue Horiuchi, Akiko Kobori, Satoshi Usami, Takeo Yoshikawa, Naoji Amano, Shinsuke Washizuka, Yuji Okazaki, Toshio Miyata
AIM: The aim of this clinical trial was to obtain proof of concept for high-dose pyridoxamine as a novel treatment for schizophrenia with enhanced carbonyl stress. METHODS: Ten Japanese schizophrenia patients with high plasma pentosidine, which is a representative biomarker of enhanced carbonyl stress, were recruited in a 24 week, open trial in which high-dose pyridoxamine (ranging from 1200 to 2400 mg/day) was administered using a conventional anti-psychotic regimen...
October 24, 2017: Psychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/29055745/apigenin-as-neuroprotective-agent-of-mice-and-men
#6
REVIEW
Seyed Fazel Nabavi, Haroon Khan, Grazia D'onofrio, Dunja Šamec, Samira Shirooie, Ahmad Reza Dehpour, Sandro Argüelles Castilla, Solomon Habtemariam, Eduardo Sobarzo-Sanchez
Neurodegenerative diseases (NNDs) such as Alzheimer's and Parkinson's diseases are the most common age-related pathologies that affect millions of people all over the world. To date, effective therapy for NNDs is not available and current approaches to disease management include neuroprotection strategy with a hope of maintaining and enhancing the function of survising neurons. Of course, such an approach by its own will not offer a cure but is likely to delay the disease progression by ameliorating the increase of neurotoxic agents such reactive oxygen species (ROS) and the associated inflammatory cascades...
October 18, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/29047301/pimavanserin-novel-pharmacotherapy-for-parkinson-s-disease-psychosis
#7
Zeyad T Sahli, Frank I Tarazi
Pimavanserin is the first FDA-approved atypical antipsychotic drug indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Areas covered: This review focuses on the preclinical discovery of pimavanserin. It analyzes the pharmacological, behavioral and molecular mechanisms of pimavanserin and their contribution to the therapeutic advantages of the drug as reported in published preclinical and clinical studies, and product labels. Expert opinion: Pimavanserin exhibits a unique pharmacological profile with nanomolar affinity at serotonin 5-HT2A and 5-HT2C receptors...
October 19, 2017: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/29043906/parkinson-s-disease-and-the-quest-for-preclinical-diagnosis-an-interview-with-professor-werner-poewe
#8
Werner Poewe
Werner Poewe speaks to Laura Dormer, Editorial Director: Professor Werner Poewe is Professor of Neurology and Director of the Department of Neurology at Innsbruck Medical University in Innsbruck, Austria. He held a Residency in Clinical Neurology and Psychiatry at the University of Innsbruck, Austria, from 1977 to 1984. From 1984 to 1985 he teamed up with Gerald Stern and Andrew Lees as a British Council Research Fellow at University College and Middlesex Hospital's Medical School in London to perform clinical studies into levodopa-induced dystonia and pharmacokinetics of levodopa in naive versus L-Dopa treated Parkinson's disease...
October 18, 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/28980176/effects-of-dance-practice-on-functional-mobility-motor-symptoms-and-quality-of-life-in-people-with-parkinson-s-disease-a-systematic-review-with-meta-analysis
#9
REVIEW
Marcela Dos Santos Delabary, Isabel Giovannini Komeroski, Elren Passos Monteiro, Rochelle Rocha Costa, Aline Nogueira Haas
BACKGROUND: Patients with Parkinson's Disease (PD) undergo motor injuries, which decrease their quality of life (QL). Dance, added to drug therapy, can help treating these patients AIMS: To conduct a systematic review with meta-analysis with the aim to analyze the effects of dance classes in comparison to other interventions or to the absence of intervention, in randomized clinical trials (RCTs), on functional mobility, motor symptoms and QL of PD patients METHODS: The search was conducted in MEDLINE, LILACS, SciELO, Cochrane and PsycINFO (last searched in August 2017)...
October 4, 2017: Aging Clinical and Experimental Research
https://www.readbyqxmd.com/read/28927992/protective-effects-of-the-glp-1-mimetic-exendin-4-in-parkinson-s-disease
#10
REVIEW
Dilan Athauda, Thomas Foltynie
There is increasing interest in the potential role of glucagon-like peptide-1 (GLP-1) receptor agonists as neuroprotective treatments in neurodegenerative diseases including Parkinson's disease following the publication of the results of the Exenatide-PD trial. Of the current GLP-1 receptor agonists already licensed to treat Type 2 diabetes several including exenatide, liraglutide and lixisenatide are the subject of ongoing clinical trials in PD. The underlying rationale for using drugs licensed and effective for T2DM in PD patients therefore needs to be scrutinized, and the results obtained to date critically reviewed...
September 18, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28920562/comparison-of-general-and-local-anesthesia-for-deep-brain-stimulator-insertion-a-systematic-review
#11
Veena Sheshadri, Nathan C Rowland, Jigesh Mehta, Marina Englesakis, Pirjo Manninen, Lashmi Venkatraghavan
BACKGROUND: Subthalamic nucleus deep brain stimulation (STN-DBS) has become a standard treatment for many patients with Parkinson's disease (PD). The reported clinical outcome measures for procedures done under general anesthesia (GA) compared to traditional local anesthetic (LA) technique are quite heterogeneous and difficult to compare. The aim of this systematic review and metaanalysis was to determine whether the clinical outcome after STN-DBS insertion under GA is comparable to that under LA in patients with Parkinson's disease...
September 18, 2017: Canadian Journal of Neurological Sciences. le Journal Canadien des Sciences Neurologiques
https://www.readbyqxmd.com/read/28895186/the-placebo-effect-on-bradykinesia-in-parkinson-s-disease-with-and-without-prior-drug-conditioning
#12
Elisa Frisaldi, Elisa Carlino, Maurizio Zibetti, Diletta Barbiani, Francesca Dematteis, Michele Lanotte, Leonardo Lopiano, Fabrizio Benedetti
BACKGROUND: Placebo effects represent a major drawback in clinical trials, and their magnitude hampers the development of new treatments. Previous research showed that prior exposure to active treatments increases the placebo response for muscle rigidity in Parkinson's disease. METHODS: We investigated the effects of prior exposure to apomorphine on the placebo response of another cardinal symptom of Parkinson's disease, bradykinesia, by a movement time analyzer...
September 12, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28880354/-pimavanserin-a-new-treatment-for-the-parkinson-s-disease-psychosis
#13
J H Duits, M S Ongering, H J M Martens, P F J Schulte
Clozapine is an effective drug for treating psychosis in Parkinson's disease (PDP) and is registered as such in the Netherlands. However, clozapine can have adverse effects, including agranulocytosis. The new drug pimavanserin was recently registered in the United States for the treatment of PDP.<br/> AIM: To review the literature on pimavanserin and discuss the position it currently occupies in the Netherlands as a potential treatment for PDP.<br/> METHOD: Systematic search of the literature.<br/> RESULTS: We found reports on four randomised controlled trials (RCTs), one review and six articles about the pharmacokinetics and pharmacodynamics of pimavanserin...
2017: Tijdschrift Voor Psychiatrie
https://www.readbyqxmd.com/read/28872217/adverse-effects-produced-by-different-drugs-used-in-the-treatment-of-parkinson-s-disease-a-mixed-treatment-comparison
#14
Bao-Dong Li, Zhen-Yun Bi, Jing-Feng Liu, Wei-Jun Si, Qian-Qian Shi, Li-Peng Xue, Jing Bai
OBJECTIVE: This mixed treatment comparison is used to compare the adverse effects of eleven different drugs used to treat Parkinson's disease (PD). The drugs that we compare include the following: ropinirole, rasagiline, rotigotine, entacapone, apomorphine, pramipexole, sumanirole, bromocriptine, piribedil, pergolide, and levodopa. METHODS: PubMed, EMBASE, and Cochrane Library were searched from the inception to December 2015. Our analysis combines the evidences of direct comparison and indirect comparison between various literatures...
October 2017: CNS Neuroscience & Therapeutics
https://www.readbyqxmd.com/read/28861893/glitazone-use-associated-with-reduced-risk-of-parkinson-s-disease
#15
Brage Brakedal, Irene Flønes, Simone F Reiter, Øivind Torkildsen, Christian Dölle, Jörg Assmus, Kristoffer Haugarvoll, Charalampos Tzoulis
BACKGROUND: Whether antidiabetic glitazone drugs protect against Parkinson's disease remains controversial. Although a single clinical trial showed no evidence of disease modulation, retrospective studies suggest that a disease-preventing effect may be plausible. The objective of this study was to examine if the use of glitazone drugs is associated with a lower incidence of PD among diabetic patients. METHODS: We compared the incidence of PD between individuals with diabetes who used glitazones, with or without metformin, and individuals using only metformin in the Norwegian Prescription Database...
September 1, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28841828/blink-rate-is-associated-with-drug-induced-parkinsonism-in-patients-with-severe-mental-illness-but-does-not-meet-requirements-to-serve-as-a-clinical-test-the-curacao-extrapyramidal-syndromes-study-xiii
#16
Charlotte L Mentzel, P Roberto Bakker, Jim van Os, Marjan Drukker, Glenn E Matroos, Marina A J Tijssen, Peter N van Harten
BACKGROUND: Drug-induced parkinsonism (DIP) has a high prevalence and is associated with poorer quality of life. To find a practical clinical tool to assess DIP in patients with severe mental illness (SMI), the association between blink rate and drug-induced parkinsonism (DIP) was assessed. METHODS: In a cohort of 204 SMI patients receiving care from the only mental health service of the previous Dutch Antilles, blink rate per minute during conversation was assessed by an additional trained movement disorder specialist...
August 25, 2017: Journal of Negative Results in Biomedicine
https://www.readbyqxmd.com/read/28836869/renin-angiotensin-system-as-a-potential-target-for-new-therapeutic-approaches-in-parkinson-s-disease
#17
REVIEW
Santiago Perez-Lloret, Matilde Otero-Losada, Jorge E Toblli, Francisco Capani
Currently, available therapies for Parkinson's disease (PD) are symptomatic. Therefore, the search for neuroprotective drugs remains a top priority. Areas covered: In this review, the potential symptomatic or disease-modifying effect of drugs targeting the Renin-Angiotensin System (RAS) in PD will be explored. Expert opinion: The importance of nigrostriatal local RAS has only begun to be unraveled in the last decades. On one hand, there is a complex feedback cycle between RAS and dopamine (DA). On the other hand, RAS affects dopaminergic neurons vulnerability...
October 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28833562/randomized-placebo-controlled-trial-of-ads-5102-amantadine-extended-release-capsules-for-levodopa-induced-dyskinesia-in-parkinson-s-disease-ease-lid-3
#18
Wolfgang Oertel, Karla Eggert, Rajesh Pahwa, Caroline M Tanner, Robert A Hauser, Claudia Trenkwalder, Reinhard Ehret, Jean Philippe Azulay, Stuart Isaacson, Larissa Felt, Mary Jean Stempien
BACKGROUND: The treatment of levodopa-induced dyskinesia in Parkinson's disease (PD) is an unmet need with no approved drug therapy. OBJECTIVE: The purpose of this study was to investigate the efficacy and safety of 274 mg ADS-5102 (amantadine) extended-release capsules (equivalent to 340-mg amantadine HCl) for levodopa-induced dyskinesia in a randomized controlled trial. METHODS: PD patients with ≥1 hour of troublesome dyskinesia and at least mild functional impact were randomized to placebo or ADS-5102 once daily at bedtime for 13 weeks...
August 21, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28820437/are-astrocytes-the-predominant-cell-type-for-activation-of-nrf2-in-aging-and-neurodegeneration
#19
REVIEW
Jeffrey R Liddell
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that regulates hundreds of antioxidant genes, and is activated in response to oxidative stress. Given that many neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease and multiple sclerosis are characterised by oxidative stress, Nrf2 is commonly activated in these diseases. Evidence demonstrates that Nrf2 activity is repressed in neurons in vitro, and only cultured astrocytes respond strongly to Nrf2 inducers, leading to the interpretation that Nrf2 signalling is largely restricted to astrocytes...
August 18, 2017: Antioxidants (Basel, Switzerland)
https://www.readbyqxmd.com/read/28818104/neuroprotective-properties-of-curcumin-in-toxin-base-animal-models-of-parkinson-s-disease-a-systematic-experiment-literatures-review
#20
Xin-Shi Wang, Zeng-Rui Zhang, Man-Man Zhang, Miao-Xuan Sun, Wen-Wen Wang, Cheng-Long Xie
BACKGROUND: Curcumin (diferuloylmethane), a polyphenol extracted from the plant Curcuma longa, is widely used in Southeast Asia, China and India in food preparation and for medicinal purposes. Meanwhile, the neuroprotective actions of curcumin have been documented for experimental therapy in Parkinson's disease (PD). METHODS: In this study, we used a systematic review to comprehensively assess the efficacy of curcumin in experimental PD. Using electronic and manual search for the literatures, we identified studies describing the efficacy of curcumin in animal models of PD...
August 17, 2017: BMC Complementary and Alternative Medicine
keyword
keyword
18959
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"